# Diabetes Research Hub — Monitor Review Report

**Run date:** 2026-06-14 (automated, unattended)
**Reviewer:** Hub Monitor scheduled task
**Scope:** Review of latest script outputs, snapshot diffs, gap analysis, and a 7-day breaking-news web check. This is a **read-only review** — no hub files were modified.

---

## TL;DR — What's Actionable

1. **FDA approved teplizumab (TZIELD, Sanofi) for children aged 8+ with Stage 3 T1D** — reported 2026-06-13 (STAT). This is a genuine **new FDA action** since yesterday's run and the headline external item. The agency missed its April 21 target date; approval came through the expedited-review pathway. Teplizumab is already the most active cross-domain cluster in our PubMed feed (11 mentions in the latest snapshot). *Worth a tracker entry + evidence review.*
2. **Tegoprubart islet-transplant data at ADA 2026** — all 12 trial participants who received deceased-donor islet transplants plus tegoprubart (anti-CD40L, every 3 weeks) are off external insulin. Directly relevant to our **T1D Cure & Cell Therapy** corpus (153 trials) and the islet-transplant gap cluster.
3. **Trial feed is completely quiet:** the automated diff (06-13 → 06-14) shows **0 new, 0 removed, 0 status changes, 0 newly posted results.** Corpus holds steady at 809 unique trials.
4. **PubMed/gap data is now 2 days stale.** `pubmed_recent_latest.json` is dated **2026-06-12**; clinical-trials data refreshed cleanly to **2026-06-14**. Re-run `baseline_pubmed_alerts.py` to resync.
5. Retatrutide TRIUMPH Phase 3 readout (ADA, June 6) was already captured in the 06-13 report — no longer new, but the peer-reviewed primaries are still pending for GOLD-level evidence.

---

## File System Status

| File | Last modified | Status |
|------|--------------|--------|
| `clinical_trials_latest.json` | 2026-06-14 07:05 | ✅ Current |
| `clinical_trials_summary.md` | 2026-06-14 07:05 | ✅ Current |
| `hub_monitor_report.md` | 2026-06-14 07:05 | ✅ Current |
| `pubmed_recent_latest.json` | 2026-06-12 07:05 | ⚠️ 2 days old |
| `literature_gap_report.md` | 2026-06-13 08:10 | ✅ Current (regenerated) |
| `literature_gap_data.json` | 2026-04-20 15:35 | ⚠️ ~55 days old (raw gap dataset) |

**Notes:**
- All four expected core outputs exist; none missing.
- `hub_monitor.py` flags **713 result files older than 14 days** (up from 709 yesterday). Expected for archived daily snapshots — flagged for awareness only.
- The human-readable gap *report* was regenerated 06-13 (driven by `gap_evidence.json`), but the underlying raw gap *dataset* (`literature_gap_data.json`) still dates to 2026-04-20.
- Stale Excel lock file (`.~lock.Diabetes_Research_Tracker.xlsx#`) is still present in the hub root — the tracker may be open/locked on the user's machine, which will block the next automated tracker write.

---

## Clinical Trial Changes (vs. 2026-06-13 snapshot)

**Diff summary:** 0 new · 0 removed · 0 status changes · 0 newly posted results.
**Corpus totals:** 809 unique trials — 262 RECRUITING · 141 NOT_YET_RECRUITING · 107 ACTIVE_NOT_RECRUITING · 292 COMPLETED. 124 are PHASE3.

No movement in the trial feed today. Key Phase 3 programs being tracked remain unchanged from the 06-13 run:

| Therapy / Program | Sponsor | Status |
|---|---|---|
| **VX-880 (zimislecel)** islet cell therapy | Vertex | RECRUITING |
| **Baricitinib** (beta-cell preservation) | Eli Lilly | RECRUITING |
| **Orforglipron** (oral GLP-1) | Eli Lilly | NOT_YET / ACTIVE / COMPLETED |
| **Retatrutide** (triple agonist) | Eli Lilly | ACTIVE_NOT_RECRUITING |
| **CagriSema** | Novo Nordisk | RECRUITING / NOT_YET / ACTIVE |
| **Insulin icodec (weekly)** | Novo Nordisk | RECRUITING / NOT_YET |
| **Teplizumab** | various | RECRUITING / ACTIVE — *see FDA pediatric approval below* |

> ⚠️ Data note (unchanged): `has_results` is still `false` for all 809 trials despite 292 in the "Recently Completed with Results" category. The "newly posted results" detector remains blind until this field is populated in `baseline_clinical_trials.py`. No Sana Biotechnology trials appear in the corpus.

---

## PubMed Highlights (data as of 2026-06-12, 165 unique papers)

The underlying snapshot is unchanged from yesterday (data is 2 days stale). The most recent automated snapshot diff covered **06-11 → 06-12: 39 new / 37 dropped papers**, with **5 cross-domain new papers**:

- **[42277427]** Lentiviral GLP-1 gene therapy → stage-dependent β-cell regeneration — *T2D GLP-1 + Gene Therapy* (novel mechanism)
- **[42269843]** Shared immune pathways in MS and T1D — *Immunotherapy + teplizumab*
- **[42276507]** Oxidative-stress profiling + retinal imaging — *Biomarker + Complications*
- **[42268809]** Microbiome-informed prediction of pregnancy complications — *Biomarker + Microbiome*
- **[42270051]** *L. casei* Zhang, hippocampal metabolism/cognition in T2DM rats — *Biomarker + Microbiome*

### Key-therapy mention counts (latest snapshot)
orforglipron 12 · CagriSema 12 · teplizumab 11 · icodec 11 · dapagliflozin 11 · retatrutide 10 · baricitinib 9 · **zimislecel 1** (first appearance — previously 0).

The teplizumab cluster remains the strongest cross-domain signal, which now aligns with the FDA pediatric approval below.

---

## Gap Analysis Summary (BRONZE confidence — single analytical source)

Top under-researched intersections (Gap Score 100 = essentially no co-publication), unchanged from the 06-13 regeneration:

| Rank | Intersection | Joint Pubs | Why it may matter |
|---|---|---|---|
| 1 | **Beta Cell Regen × Health Equity** | 0 | No equity analysis of who can access emerging regenerative/cell therapies |
| 2 | **Insulin Resistance × Islet Transplant** | 1 | IR in graft recipients affects survival; barely studied |
| 3 | **Islet Transplant × Drug Repurposing** | 0 | Existing immunosuppressants could be screened for islet protection |
| 4 | **Islet Transplant × Health Equity** | 0 | Islet transplant access limited to select centers; no equity work |
| 5 | **Gene Therapy × LADA** | 0 | LADA's autoimmune mechanism makes it a gene-therapy candidate; no crossover |

### Alignment with Tier-1 Doctrine areas
- **Drug Repurposing** (Tier-1 #4) → gap #3 supports the islet-immunosuppressant repurposing work already in the hub.
- **Health Equity / Epidemiology** (Tier-1 #6) → recurs across gaps #1 and #4; equity overlays on cell/immunotherapies are defensible and data-available.
- The tegoprubart islet result (ADA) gives a timely, concrete hook for the **Islet Transplant × Drug Repurposing / Health Equity** synthesis targets.

All gap classifications remain **BRONZE / preliminary** and require expert confirmation + Cochrane/PROSPERO cross-check before any published claim.

---

## Breaking News (7-day web check)

**🔬 NEW — FDA approves teplizumab (TZIELD, Sanofi) for children aged 8+ with Stage 3 T1D (2026-06-13).**
First approval extending teplizumab to a pediatric Stage 3 (clinical-onset) population; cleared via the expedited-review pathway after the agency missed its April 21 goal date. This is the week's headline regulatory action and corroborates the standing teplizumab momentum in our PubMed feed.
*Evidence level: regulatory/news tier — confirm against the FDA label and prescribing information for GOLD.*

**🔬 Significant (ADA 2026, June 5–8) — Tegoprubart islet-transplant data.**
All 12 participants who received deceased-donor islet transplants plus tegoprubart (anti-CD40L, every 3 weeks) were off external insulin. Relevant to the T1D cure/cell-therapy corpus and the islet-transplant gap cluster.
*Evidence level: conference-presentation tier — peer-reviewed primary pending for GOLD.*

**Context (already reported 06-13, not new):**
- Retatrutide TRIUMPH Phase 3 readout (ADA, June 6) — first triple-hormone GIP/GLP-1/glucagon agonist for T2D + obesity, with OSA and knee-OA pain benefits.
- ADA released the **Standards of Care in Diabetes — 2026** (CGM at onset; relaxed prerequisites for CSII/AID initiation).

**Older regulatory context:** Awiqli (weekly icodec, 2026-03-26); generic dapagliflozin (2026-04-07); Langlara glargine biosimilar (2026-04-29). No additional *new* FDA diabetes approval beyond teplizumab in the last 7 days.

---

## Recommended Actions

1. **Add a tracker entry for the teplizumab pediatric FDA approval** (Sanofi/TZIELD, Stage 3 T1D, ages 8+, 2026-06-13). Tag evidence level as regulatory/news; pull the FDA label for confirmation, and link the existing teplizumab PubMed cluster (incl. [42221148], [42267680], [42269843]).
2. **Log the tegoprubart islet-transplant ADA result** under T1D Cure & Cell Therapy; queue for the evidence pipeline once a primary publication or abstract ID is available.
3. **Re-sync PubMed + gap data** to match the 06-14 trial snapshot (currently 2 days behind):
   `python baseline_pubmed_alerts.py` and, if a fresh raw matrix is wanted, `python project1_literature_gap_analysis.py` (raw `literature_gap_data.json` dates to 2026-04-20).
4. **Fix `has_results` / `results_posted` population in `baseline_clinical_trials.py`** — still `false` for all 809 trials, blinding the newly-posted-results detector.
5. **Release the Excel lock** — `.~lock.Diabetes_Research_Tracker.xlsx#` is still present; close the tracker before the next automated write.
6. **Confirm the 713 stale-file flag is benign** (expected for archived daily snapshots); consider archiving older `*_snapshot_*` files out of `Analysis/Results/` to cut monitor noise.
7. **Prioritize Tier-1-aligned gaps for synthesis:** Islet Transplant × Drug Repurposing and Beta Cell Regen × Health Equity remain the most defensible next targets; the tegoprubart result adds timely relevance. Validate against Cochrane/PROSPERO first (Doctrine requirement).

---

*Generated by the Diabetes Hub Monitor scheduled task — read-only review run, 2026-06-14. No source files were modified. New external claims carry the evidence level noted inline, per RESEARCH_DOCTRINE.md.*
